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![*In vitro* drug release and penetration of 1% diclofenac sodium containing 1% Carbomer 934 P gel (DC1)](scipharm.2010.78.597f1){#f1-scipharm.2010.78.597}

![*In vivo* paw edema test of 1 % diclofenac sodium containing 1% Carbomer 934 P(DC1)](scipharm.2010.78.597f2){#f2-scipharm.2010.78.597}
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  **minutes**   **Formulation A**   **Formulation B**                                                             
  ------------- ------------------- ------------------- -------- -------- ------- ------- ------- ------- ------- -------
  **S.V.**      85.34               99.05               100.79   100.39   99.88   99,08   98,49   97,90   97,36   96,89
  **SD**        4.65                2.57                3.20     3.34     3.31    1,32    1,32    1,28    1,27    1,28
  **RSD**       5.45                2.60                3.17     3.32     3.31    1,33    1,34    1,31    1,31    1,32
  **f2**                                                                  68,15                                   99,44

![Percentage of released drug after 7h of release in dependence on stirring rate](scipharm.2010.78.612f1){#f1-scipharm.2010.78.612}

![Stereomicroscopic view of co-extrudates. Arrow shows void space between two parts of cylinder.](scipharm.2010.78.612f2){#f2-scipharm.2010.78.612}
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![Shape and hydration levels for the HPMC-TP 1:1 matrices subjected to the hydration. Snapshot of cut matrices (experimental) and superimposed simulated profiles (model) after 12 hours of hydration. The initial, non-swollen half-matrices shape is a rectangle (diameter 13 mm, semi-thickness 1.1 mm).](scipharm.2010.78.625f1){#f1-scipharm.2010.78.625}
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![Images of samples taken during spheronization after different for a pure MCC formulation](scipharm.2010.78.640f1){#f1-scipharm.2010.78.640}
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  **Min**              5       10      15      20      25      30       f2
  -------------------- ------- ------- ------- ------- ------- -------- -------
  **Sample 1**                                                          
                                                                        
  **% dissolution**    24,29   47,88   68,32   86,01   98,99   100,35   
  **SD**               1,29    3,31    3,99    4,44    3,54    1,39     
  **RSD**              5,33    6,91    5,84    5,17    3,58    1,39     75.21
                                                                        
  **Sample 2**                                                          
                                                                        
  **% dissolution**    21,42   43,00   62,35   78,86   91,72   97,85    
  **SD**               2,57    4,07    5,07    5,69    4,95    1,99     
  **RSD**              11,98   9,46    8,13    7,22    5,40    2,04     78,22
                                                                        
  **Sample3**                                                           
                                                                        
  **% dissolution**    22,18   44,78   65,45   82,85   95,47   98,47    
  **SD**               3,60    5,78    6,65    6,38    4,20    1,02     
  **RSD**              16,21   12,90   10,15   7,70    4,40    1,04     99.18
                                                                        
  **Reference drug**                                                    
                                                                        
  **% dissolution**    22,28   44,96   65,41   82,66   94,84   98,52    
  **SD**               4,00    8,20    9,90    12,10   11,10   6,41     
  **RSD**              17,95   18,25   15,13   14,64   11,70   6,51     

![Film formation on a single vertical tablet after 0.3 s in the spray zone.](scipharm.2010.78.663f1){#f1-scipharm.2010.78.663}
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![Imaging of internalized SLN (marked with arrows) located next to the nuclei (rounded structure). A - SLN-SPP are seen distinctly as (blue) dots, while B - SLN-C are hardly recognized due to the broadly distributed fluorescence from 6-coumarin (green). Bar is 10 μm.](scipharm.2010.78.682f1){#f1-scipharm.2010.78.682}
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